Epigenetics in ovarian cancer

Devouassoux-Shisheboran, 2015, Pathobiology of ovarian carcinomas, Chin. J. Cancer, 34, 50, 10.5732/cjc.014.10273 Faber, 2013, Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies, Cancer Causes Control: CCC, 24, 989, 10.1007/s10552-013-0174-4 Pearce, 2012, Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies, Lancet Oncol., 13, 385, 10.1016/S1470-2045(11)70404-1 Pearce, 2008, Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis, Br. J. Cancer, 98, 282, 10.1038/sj.bjc.6604170 Bonome, 2005, Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary, Cancer Res., 65, 10602, 10.1158/0008-5472.CAN-05-2240 Tothill, 2008, Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome, Clin. Cancer Res., 14, 5198, 10.1158/1078-0432.CCR-08-0196 Zorn, 2005, Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer, Clin. Cancer Res., 11, 6422, 10.1158/1078-0432.CCR-05-0508 Vaughan, 2011, Rethinking ovarian cancer: recommendations for improving outcomes, Nat. Rev. Cancer, 11, 719, 10.1038/nrc3144 Klinkebiel, 2016, DNA methylome analyses implicate fallopian tube epithelia as the origin for high-Grade serous ovarian cancer, Mol. Cancer Res., 14, 787, 10.1158/1541-7786.MCR-16-0097 Ciriello, 2013, Emerging landscape of oncogenic signatures across human cancers, Nat. Genet., 45, 1127, 10.1038/ng.2762 Patch, 2015, Whole-genome characterization of chemoresistant ovarian cancer, Nature, 521, 489, 10.1038/nature14410 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 Vang, 2009, Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems, Adv. Anat. Pathol., 16, 267, 10.1097/PAP.0b013e3181b4fffa Chen, 2014, A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology, Onco Targets Ther., 7, 1891, 10.2147/OTT.S67812 Marquez, 2005, Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon, Clin. Cancer Res., 11, 6116, 10.1158/1078-0432.CCR-04-2509 Yamaguchi, 2014, Epigenetic and genetic dispositions of ovarian carcinomas, Oncoscience, 1, 574, 10.18632/oncoscience.82 Yamaguchi, 2010, Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes, Oncogene, 29, 1741, 10.1038/onc.2009.470 Shen, 2013, SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen, PLoS One, 8, e75564, 10.1371/journal.pone.0075564 Shen, 2013, Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer, Nat. Commun., 4, 1628, 10.1038/ncomms2629 Cicek, 2013, Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel, Hum. Mol. Genet., 22, 3038, 10.1093/hmg/ddt160 Bojesen, 2013, Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer, Nat. Genet., 45, 371, 10.1038/ng.2566 Chornokur, 2015, Common genetic variation In cellular transport genes and epithelial ovarian cancer (EOC) risk, PLoS One, 10, e0128106, 10.1371/journal.pone.0128106 Gayther, 2010, The inherited genetics of ovarian and endometrial cancer, Curr. Opin. Genet. Dev., 20, 231, 10.1016/j.gde.2010.03.001 Kuchenbaecker, 2015, Identification of six new susceptibility loci for invasive epithelial ovarian cancer, Nat. Genet., 47, 164, 10.1038/ng.3185 Lynch, 1991, Hereditary ovarian cancer pedigree studies, part II, Cancer Genet. Cytogenet., 53, 161, 10.1016/0165-4608(91)90094-B Shulman, 2010, Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome, Obstet. Gynecol. Clin. North Am., 37, 109, 10.1016/j.ogc.2010.03.003 Song, 2009, A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2, Nat. Genet., 41, 996, 10.1038/ng.424 Jones, 2007, The epigenomics of cancer, Cell, 128, 683, 10.1016/j.cell.2007.01.029 Lichtenstein, 2000, Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland, N. Engl. J. Med., 343, 78, 10.1056/NEJM200007133430201 Bird, 1985, A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA, Cell, 40, 91, 10.1016/0092-8674(85)90312-5 Belshaw, 2004, Long-term reinfection of the human genome by endogenous retroviruses, Proc. Natl. Acad. Sci. U. S. A., 101, 4894, 10.1073/pnas.0307800101 Moore, 2013, DNA methylation and its basic function, Neuropsychopharmacology, 38, 23, 10.1038/npp.2012.112 Widschwendter, 2004, DNA hypomethylation and ovarian cancer biology, Cancer Res., 64, 4472, 10.1158/0008-5472.CAN-04-0238 Goodier, 2008, Retrotransposons revisited: the restraint and rehabilitation of parasites, Cell, 135, 23, 10.1016/j.cell.2008.09.022 Ziller, 2011, Genomic distribution and inter-sample variation of non-CpG methylation across human cell types, PLoS Genet., 7, e1002389, 10.1371/journal.pgen.1002389 Wu, 2016, DNA methylation on N(6)-adenine in mammalian embryonic stem cells, Nature, 532, 329, 10.1038/nature17640 Stricker, 2017, From profiles to function in epigenomics, Nat. Rev. Genet., 18, 51, 10.1038/nrg.2016.138 Boland, 2010, Microsatellite instability in colorectal cancer, Gastroenterology, 138, 2073, 10.1053/j.gastro.2009.12.064 Miller, 2016, The emergence of pan-cancer CIMP and its elusive interpretation, Biomolecules, 6, 10.3390/biom6040045 Yang, 2014, Gene body methylation can alter gene expression and is a therapeutic target in cancer, Cancer Cell, 26, 577, 10.1016/j.ccr.2014.07.028 Mendizabal, 2017, Body-hypomethylated human genes harbor extensive intragenic transcriptional activity and are prone to cancer-associated dysregulation, Nucleic Acids Res., 10.1093/nar/gkx020 Zeimet, 2011, DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer, Gynecol. Oncol., 121, 24, 10.1016/j.ygyno.2010.12.332 Ehrlich, 2009, DNA hypomethylation in cancer cells, Epigenomics, 1, 239, 10.2217/epi.09.33 Chi, 2010, Covalent histone modifications–miswritten, misinterpreted and mis-erased in human cancers, Nat. Rev. Cancer, 10, 457, 10.1038/nrc2876 Li, 2017, Bivalent histone modifications and development, Curr. Stem Cell Res. Ther., 12, 1 Verdin, 2003, Class II histone deacetylases: versatile regulators, Trends Genet., 19, 286, 10.1016/S0168-9525(03)00073-8 Nakagawa, 2007, Expression profile of class I histone deacetylases in human cancer tissues, Oncol. Rep., 18, 769 Pchejetski, 2016, Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer, J. Cancer Res. Clin. Oncol., 142, 1659, 10.1007/s00432-015-2064-5 Ceccacci, 2016, Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia, Br. J. Cancer, 114, 605, 10.1038/bjc.2016.36 Shi, 2014, The mechanisms behind the therapeutic activity of BET bromodomain inhibition, Mol. Cell, 54, 728, 10.1016/j.molcel.2014.05.016 Yang, 2006, Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data, BMC Cancer, 6, 212, 10.1186/1471-2407-6-212 Press, 2008, Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities, BMC Cancer, 8, 17, 10.1186/1471-2407-8-17 Helleman, 2006, Mismatch repair and treatment resistance in ovarian cancer, BMC Cancer, 6, 201, 10.1186/1471-2407-6-201 Ibanez de Caceres, 2004, Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients, Cancer Res., 64, 6476, 10.1158/0008-5472.CAN-04-1529 Ozdemir, 2012, Methylation of tumor suppressor genes in ovarian cancer, Exp. Ther. Med., 4, 1092, 10.3892/etm.2012.715 Strathdee, 2001, Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes, Am. J. Pathol., 158, 1121, 10.1016/S0002-9440(10)64059-X Wiley, 2006, Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential, Cancer, 107, 299, 10.1002/cncr.21992 Furlan, 2006, The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas, Clin. Cancer Res., 12, 3329, 10.1158/1078-0432.CCR-05-2679 Feng, 2008, DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma, Gynecol. Oncol., 111, 320, 10.1016/j.ygyno.2008.07.036 Makarla, 2005, Promoter hypermethylation profile of ovarian epithelial neoplasms, Clin. Cancer Res., 11, 5365, 10.1158/1078-0432.CCR-04-2455 Moselhy, 2013, Hypermethylation of P15, P 16, and E-cadherin genes in ovarian cancer, Toxicol. Ind. Health, 31, 924, 10.1177/0748233713484657 Niederacher, 1999, CDKN2A gene inactivation in epithelial sporadic ovarian cancer, Br. J. Cancer, 80, 1920, 10.1038/sj.bjc.6690621 Teodoridis, 2005, CpG island methylation of DNA damage response genes in advanced ovarian cancer, Cancer Res., 65, 8961, 10.1158/0008-5472.CAN-05-1187 Esteller, 2000, Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors, J. Natl. Cancer Inst., 92, 564, 10.1093/jnci/92.7.564 Houshdaran, 2010, DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines, PLoS One, 5, e9359, 10.1371/journal.pone.0009359 Yoon, 2010, High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array, Oncol. Rep., 24, 917 Shih Ie, 2010, Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis, Am. J. Obstet. Gynecol., 203, e1 Yoon, 2001, Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas, Int. J. Cancer, 94, 212, 10.1002/ijc.1466 Kolbe, 2012, Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype, PLoS One, 7, e32941, 10.1371/journal.pone.0032941 Sanchez-Vega, 2013, Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines, Epigenetics, 8, 1355, 10.4161/epi.26701 Hafner, 2015, RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer, Int. J. Cancer, 138, 217, 10.1002/ijc.29690 Earp, 2015, DNA methylation changes in epithelial ovarian cancer histotypes, Genomics, 106, 311, 10.1016/j.ygeno.2015.09.001 Whitcomb, 2003, Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma, Clin. Cancer Res., 9, 2277 Pharoah, 2013, GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer, Nat. Genet., 45, 362, 10.1038/ng.2564 Ross-Adams, 2016, HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer, Oncotarget, 7, 74734, 10.18632/oncotarget.12543 Thiery, 2002, Epithelial-mesenchymal transitions in tumour progression, Nat. Rev. Cancer, 2, 442, 10.1038/nrc822 Arildsen, 2017, Involvement of chromatin remodeling genes and the rho GTPases RhoB and CDC42 in ovarian clear cell carcinoma, Front. Oncol., 7, 109, 10.3389/fonc.2017.00109 Jones, 2010, Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma, Science, 330, 228, 10.1126/science.1196333 Jang, 2009, Expression and prognostic significance of SIRT1 in ovarian epithelial tumours, Pathology (Phila.), 41, 366 He, 2015, Decreased expression of H3K27me3 in human ovarian carcinomas correlates with more aggressive tumor behavior and poor patient survival, Neoplasma, 62, 932, 10.4149/neo_2015_113 Bapat, 2005, Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer, Cancer Res., 65, 3025, 10.1158/0008-5472.CAN-04-3931 Singh, 2015, Evaluation of epigenetic drug targeting of heterogenous tumor cell fractions using potential biomarkers of response in ovarian cancer, Clin. Cancer Res., 21, 5151, 10.1158/1078-0432.CCR-15-0505 Chapman-Rothe, 2013, Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells, Oncogene, 32, 4586, 10.1038/onc.2012.477 Widschwendter, 2013, Epigenetics makes its mark on women-specific cancers–an opportunity to redefine oncological approaches?, Gynecol. Oncol., 128, 134, 10.1016/j.ygyno.2012.09.027 Abbosh, 2006, Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells, Cancer Res., 66, 5582, 10.1158/0008-5472.CAN-05-3575 Vella, 2011, ‘Genetic profiling' and ovarian cancer therapy (review), Mol. Med. Rep., 4, 771 Joerger, 2007, Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG, Clin. Pharmacokinet., 46, 1051, 10.2165/00003088-200746120-00005 Bolton, 2012, Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer, JAMA, 307, 382, 10.1001/jama.2012.20 Stefansson, 2012, BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer, Epigenetics, 7, 1225, 10.4161/epi.22561 Yang, 2011, Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer, JAMA, 306, 1557, 10.1001/jama.2011.1456 de Leon, 2016, Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer, Gynecol. Oncol., 142, 539, 10.1016/j.ygyno.2016.06.017 Lum, 2013, Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis, Gynecol. Oncol., 130, 369, 10.1016/j.ygyno.2013.05.002 Bauerschlag, 2011, Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles, Oncology, 80, 12, 10.1159/000327746 Flanagan, 2016, Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients, Clin. Cancer Res., 23, 2213, 10.1158/1078-0432.CCR-16-1754 Huang, 2013, Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers, Epigenetics, 8, 624, 10.4161/epi.24816 Momparler, 2005, Pharmacology of 5-Aza-2'-deoxycytidine (decitabine), Semin. Hematol., 42, S9, 10.1053/j.seminhematol.2005.05.002 Malik, 2014, Decitabine in the treatment of acute myeloid leukemia in elderly patients, Cancer Manage. Res., 6, 53 Smith, 2017, Epigenetic therapy for the treatment of epithelial ovarian cancer: a clinical review, Gynecol. Oncol. Rep., 20, 16 Minucci, 2006, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nat. Rev. Cancer, 6, 38, 10.1038/nrc1779 Mottamal, 2015, Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents, Molecules, 20, 3898, 10.3390/molecules20033898 Plumb, 2000, Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter, Cancer Res., 60, 6039 Li, 2009, Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis, Am. J. Obstet. Gynecol., 200, e1 Lapinska, 2016, The effects of histone deacetylase inhibitor and calpain inhibitor combination therapies on ovarian cancer cells, Anticancer Res., 36, 5731, 10.21873/anticanres.11156 Muscolini, 2008, Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells, Mol. Cancer Ther., 7, 1410, 10.1158/1535-7163.MCT-08-0299 Weberpals, 2011, The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells, Cancer Cell Int., 11, 29, 10.1186/1475-2867-11-29 Zhang, 2016, BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1, Theranostics, 6, 219, 10.7150/thno.13178 Yokoyama, 2016, BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer, Cancer Res., 76, 6320, 10.1158/0008-5472.CAN-16-0854 Garrido-Laguna, 2012, Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD anderson cancer center, Cancer, 118, 1422, 10.1002/cncr.26413 Weberpals, 2011, The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells, Cancer Cell Int., 11, 29, 10.1186/1475-2867-11-29 Weichert, 2008, Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas, Neoplasia, 10, 1021, 10.1593/neo.08474 Khabele, 2007, Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy, Cancer Biol. Ther., 6, 795, 10.4161/cbt.6.5.4007 Tomar, 2016, Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways, Genome Med., 8, 107, 10.1186/s13073-016-0361-5 Falchook, 2013, Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies, Invest. New Drugs, 31, 1192, 10.1007/s10637-013-0003-3 Fang, 2010, A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer, Cancer, 116, 4043, 10.1002/cncr.25204 Glasspool, 2014, A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer, Br. J. Cancer, 110, 1923, 10.1038/bjc.2014.116 Fang, 2014, Decitabine reactivated pathways in platinum resistant ovarian cancer, Oncotarget, 5, 3579, 10.18632/oncotarget.1961 Fu, 2011, Analysis of epigenetic alterations to proprotein convertase genes in disease, Methods Mol. Biol., 768, 231, 10.1007/978-1-61779-204-5_12 Cohen, 2016, A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors, Oncotarget Lockwood, 2012, Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins, Proc. Natl. Acad. Sci. U. S. A., 109, 19408, 10.1073/pnas.1216363109 Mertz, 2011, Targeting MYC dependence in cancer by inhibiting BET bromodomains, Proc. Natl. Acad. Sci. U. S. A., 108, 16669, 10.1073/pnas.1108190108 Kurimchak, 2016, Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer, Cell Rep., 16, 1273, 10.1016/j.celrep.2016.06.091 Beaufort, 2014, Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes, PLoS One, 9, e103988, 10.1371/journal.pone.0103988 Sonnemann, 2006, Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients, BMC Cancer, 6 Tjulandin, 2017 U. Matulonis, Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer In: M. Meyers (editor). Alix-Panabieres, 2012, Circulating tumor cells and circulating tumor DNA, Annu. Rev. Med., 63, 199, 10.1146/annurev-med-062310-094219 Stroun, 2001, About the possible origin and mechanism of circulating DNA apoptosis and active DNA release, Clin. Chim. Acta: Int. J. Clin. Chem., 313, 139, 10.1016/S0009-8981(01)00665-9 Warton, 2015, Methylation of cell-free circulating DNA in the diagnosis of cancer, Front. Mol. Biosci., 2, 13, 10.3389/fmolb.2015.00013 Wittenberger, 2014, DNA methylation markers for early detection of women's cancer: promise and challenges, Epigenomics, 6, 311, 10.2217/epi.14.20 Bettegowda, 2014, Detection of circulating tumor DNA in early- and late-stage human malignancies, Sci. Transl. Med., 6, 224ra24, 10.1126/scitranslmed.3007094 Gifford, 2004, The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients, Clin. Cancer Res., 10, 4420, 10.1158/1078-0432.CCR-03-0732 Wu, 2014, Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer, Asian Pac. J. Cancer Prev., 15, 1171, 10.7314/APJCP.2014.15.3.1171 Giannopoulou, 2017, RASSF1A promoter methylation in high-grade serous ovarian cancer: a direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA, Oncotarget, 8, 21429, 10.18632/oncotarget.15249 Liggett, 2011, Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors, Gynecol. Oncol., 120, 113, 10.1016/j.ygyno.2010.09.019 Belinsky, 2005, Gene promoter methylation in plasma and sputum increases with lung cancer risk, Clin. Cancer Res., 11, 6505, 10.1158/1078-0432.CCR-05-0625 Hsu, 2007, Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma, Cancer, 110, 2019, 10.1002/cncr.23001 Radpour, 2011, Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer, PLoS One, 6, e16080, 10.1371/journal.pone.0016080 Zhang, 2013, A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA, Gynecol. Oncol., 130, 132, 10.1016/j.ygyno.2013.04.048 Zhang, 2016, Molecular subtyping of serous ovarian cancer based on multi-omics data, Sci. Rep., 6, 26001, 10.1038/srep26001